<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839358</url>
  </required_header>
  <id_info>
    <org_study_id>MACHT</org_study_id>
    <secondary_id>07/0443</secondary_id>
    <secondary_id>07/90077</secondary_id>
    <nct_id>NCT00839358</nct_id>
  </id_info>
  <brief_title>Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation</brief_title>
  <acronym>MACHT</acronym>
  <official_title>Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternal-Infantil Vall d´Hebron Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of prolonged administration of albumin and
      midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic
      encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver
      transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver
      transplantation will include in the study. Patients will be randomized to receive albumin and
      midodrine (treatment group) or administration of placebo (saline for albumine) and tablets
      with excipients without midodrine (control group). Patients will be followed-up during 12th
      months. In the treatment group albumin will be given at a dose of 40g every 15 days and
      midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment
      that patients require by cirrhosis. The group control will receive placebo in the same way
      than the treatment group in addition with lactitol and the specific treatment that they
      require by their disease. In all the patients liver and renal function test, hormones
      determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal
      conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months.
      Before the inclusion in the study neuropsychological test and critical flicker test will be
      performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months.
      All the determinations will be repeated at any time that the patients develop any
      complication considered as an end point. In baseline conditions and at 3rd and 6th months a
      questionnaire of quality of life (SF36) will be performed. During a year of follow-up the
      number of paracentesis that patients require, the incidence of renal failure and EH and their
      relationship with hormonal activity and cytokine levels, free transplant survival and quality
      of life will be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End point: To evaluate the effect of long term administration of albumin and midodrine on the
      prevention of complications associated with cirrhosis in patients with cirrhosis awaiting for
      liver transplantation.

      Secondary end points:

        -  To evaluate improvement in the ascites control

        -  To evaluate survival at 6 and 12 months.

        -  To evaluate the relationship between the development of complications and the activity
           of vasoconstrictor systems( renin, aldosterone and norepinephrine) as well as the levels
           of cytokines (TNF, IL6 and IL10)

        -  To evaluate quality of life

        -  To evaluate the presence and outcome of MHE
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate complications (renal failure, hepatic encephalopathy, hyponatremia, infection and gastrointestinal bleeding) in patients with cirrhosis awaiting for liver transplant.</measure>
    <time_frame>When 97 patients are included (% of the whole population)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Renal Failure</condition>
  <condition>Hyponatremia</condition>
  <condition>Sepsis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Albumin plus midodrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>salin solution plus pills</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin</intervention_name>
    <description>albumine 40 g every 15 days</description>
    <arm_group_label>Albumin plus midodrine</arm_group_label>
    <arm_group_label>salin solution plus pills</arm_group_label>
    <other_name>Albumina Grifols</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.</description>
    <arm_group_label>Albumin plus midodrine</arm_group_label>
    <other_name>Gutron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline solution</description>
    <arm_group_label>salin solution plus pills</arm_group_label>
    <other_name>Grifols saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cirrhosis in the waiting list for liver transplant

          -  Patients with ascites or diuretic treatment

          -  To have written inform consent

        Exclusion Criteria:

          -  Systolic blood pressure ≥150 mmHg and or diastolic blood pressure≥90 mmHg

          -  To have been treated with transjugular intrahepatic portosystemic shunt (TIPS) or
             surgical shunts

          -  Antibiotic treatment in the previous week before the inclusion in the study

          -  Respiratory or cardiac failure

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Ginès</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Villarroel 170</city>
        <state>Barcelona</state>
        <zip>08870</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.</citation>
    <PMID>19158001</PMID>
  </reference>
  <reference>
    <citation>Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.</citation>
    <PMID>18471512</PMID>
  </reference>
  <reference>
    <citation>Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004 Jul;40(1):55-64.</citation>
    <PMID>15239086</PMID>
  </reference>
  <reference>
    <citation>Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310-8. Epub 2007 Mar 27. Review.</citation>
    <PMID>17389705</PMID>
  </reference>
  <reference>
    <citation>Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis. 2005;23(1):47-55. Review.</citation>
    <PMID>15920325</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Pere Gines</investigator_full_name>
    <investigator_title>Chief of Hepatology Unit</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>renal failure</keyword>
  <keyword>midodrine</keyword>
  <keyword>albumine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

